Ancestral lysosomal enzymes with increased activity harbor therapeutic potential for treatment of Hunter syndrome

Autor: Natalie M. Hendrikse, Anna Sandegren, Tommy Andersson, Jenny Blomqvist, Åsa Makower, Dominik Possner, Chao Su, Niklas Thalén, Agneta Tjernberg, Ulrica Westermark, Johan Rockberg, Stefan Svensson Gelius, Per-Olof Syrén, Erik Nordling

Publikováno v: iScience, Vol 24, Iss 3, Pp 102154- (2021)

Summary: We show the successful application of ancestral sequence reconstruction to enhance the activity of iduronate-2-sulfatase (IDS), thereby increasing its therapeutic potential for the treatment of Hunter syndrome—a lysosomal storage disease c

Externí odkaz: https://doaj.org/article/d39df5cce7224dbcaf4d0e1329c50468

Transport study of interleukin-1 inhibitors using a human in vitro model of the blood-brain barrier

Autor: Christina Kaiser, Elisabet O. Sjöström, Mikael Åstrand, Maxime Culot, Fabien Gosselet, Lisa Leickt, Erik Nordling

Publikováno v: Brain, Behavior & Immunity-Health
Brain, Behavior & Immunity-Health, Elsevier, 2021, 16, pp.100307. ⟨10.1016/j.bbih.2021.100307⟩
Brain, Behavior, & Immunity-Health, Vol 16, Iss, Pp 100307-(2021)
Brain, Behavior, & Immunity-Health

The proinflammatory cytokine Interleukin-1 (IL-1), with its two isoforms α and β, has important roles in multiple pathogenic processes in the central nervous system. The present study aimed to evaluate and compare the blood-to-brain distribution of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ebadcd520e81982ca96fc4d25235378e
https://hal-univ-artois.archives-ouvertes.fr/hal-03472272/document

Exploring the therapeutic potential of modern and ancestral phenylalanine/tyrosine ammonia-lyases as supplementary treatment of hereditary tyrosinemia

Autor: Stefan Svensson Gelius, Sergei Kuprin, Per-Olof Syrén, Natalie M. Hendrikse, Erik Nordling, Albin Holmberg Larsson

Publikováno v: Scientific Reports
Scientific Reports, Vol 10, Iss 1, Pp 1-13 (2020)

Phenylalanine/tyrosine ammonia-lyases (PAL/TALs) have been approved by the FDA for treatment of phenylketonuria and may harbour potential for complementary treatment of hereditary tyrosinemia Type I. Herein, we explore ancestral sequence reconstructi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1cec26990a6b2231b5ae8fba313db711
https://pubmed.ncbi.nlm.nih.gov/31992763

Stratification of responders towards eculizumab using a structural epitope mapping strategy

Autor: Patrik Strömberg, Magnus Berglund, Erik Nordling, Johan Rockberg, Anna-Luisa Volk, Mathias Uhlén, Francis Jingxin Hu

Publikováno v: Volk, A-L, Hu, F J, Berglund, M M, Nordling, E, Strömberg, P, Uhlén, M & Rockberg, J 2016, ' Stratification of responders towards eculizumab using a structural epitope mapping strategy ', Scientific Reports, vol. 6, 31365 . https://doi.org/10.1038/srep31365
Scientific Reports

The complement component 5 (C5)-binding antibody eculizumab is used to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical haemolytic uremic syndrome (aHUS). As recently reported there is a need for a precise classification of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bdbbfd87932b11ff149cee3d5f037a4c
https://doi.org/10.1038/srep31365

Colonic amyloidosis, computational analysis of the major amyloidogenic species, Serum Amyloid A

Autor: Erik Nordling, Mirna Abraham-Nordling

Publikováno v: Computational Biology and Chemistry. 39:29-34

Amyloidosis is characterized by misfolding of proteins. The clinical gastrointestinal manifestations of amyloidosis may mimic other disease, such as inflammatory bowel disease or colonic cancer. As these patients have a high risk for bleeding and poo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f73513d90d9bbd9e80d1897d85523ad
https://doi.org/10.1016/j.compbiolchem.2012.06.005